8-K
filed February 23, 2024, 6:59 PM ET
CIK 0001358403
leadership
confidence high
sentiment negative
materiality 0.75
Bellicum advances dissolution: all directors resign, Dave Maggio named CEO
BELLICUM PHARMACEUTICALS, INC
- All five directors resigned effective Feb 23, 2024; Richard Fair remains sole director.
- CEO Richard Fair resigned; Dave Maggio appointed CEO effective same day.
- Consulting agreement with Fair extended to June 30, 2024.
- Stockholders approved dissolution plan on Feb 20, 2024; company winding down.
- Resignations not related to any disagreement with the company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jon P. Stonehouse resigned as Director at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
· Jon P. Stonehouse ( Audit Committee and Compensation Committee )
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Charity D. Scripture resigned as Chief Development Officer at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- Chief Development Officer
Exact text from the filing
Charity D. Scripture resigned as Chief Development Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
James M. Daly resigned as Director at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
each of the Company’s directors listed below submitted their resignation from the Board and the committees thereof opposite their name below, effective as of February 23, 2024. · Mr. James M. Daly ( Compensation Committee, Nominating Committee and Finance Committee )
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Richard A. Fair resigned as President and Chief Executive Officer at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
Mr. Richard A. Fair resigned as President and Chief Executive Officer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Reid M. Huber resigned as Director at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
· Reid M. Huber, Ph.D. ( Audit Committee, Nominating Committee, Science Committee and Finance Committee )
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Dave Maggio was appointed as Chief Executive Officer at BELLICUM PHARMACEUTICALS, INC.
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
the Board appointed Dave Maggio to the position of Chief Executive Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Judith Klimovsky resigned as Director at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
· Judith Klimovsky M.D. ( Nominating Committee, Science Committee and Finance Committee )
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Stephen R. Davis resigned as Director at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
· Stephen R. Davis ( Audit Committee )
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Charles S. Grass resigned as Principal Accounting Officer at BELLICUM PHARMACEUTICALS, INC.
- Action
- resigned
- Role
- Principal Accounting Officer
Exact text from the filing
Charles S. Grass resigned as Principal Accounting Officer
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.